ing these diseases has enlightened the molecular pathogenesis of RCC, and moreover, provided means to improve patient management. Genetic testing enables early diagnosis of the disease, after which individuals at-risk can be guided to regular surveillance. Screening facilitates detection of presymptomatic early tumors broadening treatment options and potentially improving prognosis. Thus, identification of individuals with inherited cancer susceptibility is important as special management of these patients improves disease outcome. The purpose of this review is to provide clues for identification and management of hereditary renal cancer patients in clinical practice.
genes. Proto-oncogenes are involved in normal cellular signaling regulating cell growth and differentiation, but in human cancer, their function is enhanced through genetic alterations.
Most of the mutations in cancer genes are somatic, i.e. they occur during the lifetime of an individual. A subset of mutations may, however, be inherited. In those cases, familial clustering of cancer can be detected (Fig. 1) . The effect of the inherited genetic defects on cancer susceptibility varies from low to high (1). Predisposition to cancer is high in hereditary cancer syndromes, which are generally estimated to account for only a fraction of human cancers, <1-10 % depending on the tumor type. As several mutations are required for cancer development also in the inherited forms, it is susceptibility to cancer, and not the cancer itself, which is inherited. The likelihood of a mutation carrier developing a specific cancer varies strongly as shown below for the different types of inherited forms of renal cell cancer (RCC). Studies on hereditary cancer have proven im-
INTRODUCTION
On cellular level, cancer is a genetic disease caused by mutations accumulating in the genes controlling cell proliferation and cell death. These genetic changes provide cells with a growth advantage over the normal cell population, thus leading to malignancy. The changes include either inactivation of tumor suppressor genes or activation of oncogenes. Tumor suppressor genes are protective genes that normally limit the growth of tumors or are involved in the maintenance of genomic integrity. Oncogenes are mutated forms of normal cellular components, proto-onco-portant for understanding the molecular pathogenesis of cancer in general as mutations in the same genes cause both inherited and sporadic cancers. This is particularly true for RCC as discussed below.
Clinical signs of inherited cancer susceptibility include tumor development at an early age, bilateral disease, multiple primary tumors, association with other tumor types and positive family history (2). Most inherited cancer syndromes show autosomal dominant inheritance (see Glossary p. 109). In these cases, all descedents of a carrier have a 50 % chance of inheriting the mutation causing cancer susceptibility. The likelihood of developing cancer is, however, usually lower depending on the penetrance (see Glossary p. 109) of the specific mutation and the syndrome in question.
Familial clustering of RCC is detected in up to 2% of RCC cases (3, 4) . At present, several forms of he-reditary RCC have been characterized with specific clinical, histopathological, and genetic features. The occurrence of RCC is variable in these syndromes: it can be the main feature of the disease (as in hereditary papillary renal cell carcinoma, HPRC) or an uncommon manifestation of the disease typically characterized by other clinical symptoms (as in tuberous sclerosis). The most common form of hereditary RCC is von Hippel-Lindau disease (VHL) caused by mutations in VHL gene and predisposing to clear cell RCC (5). Susceptibility to papillary RCC is detected in hereditary leiomyomatosis and renal cell cancer (HLRCC) (6) and HPRC (7). Renal tumors are also associated with other tumor predisposition syndromes, such as tuberous sclerosis (angiomyolipomas, clear cell RCC) (8), hereditary non-polyposis colorectal cancer (HNPCC) (uroepithelial carcinoma of the renal pelvis and ureters) (9), Birt-Hogg-Dube and a HLRCC family (1B) demonstrating dominant inheritance pattern and variability in expression of tumor predisposition phenotype. In the VHL family (1A) the grandmother (marked with *) of the five at risk children is likely to have a new mutation as the family history is negative, her parents and all her nine sibs are unaffected. Clinical signs of inherited cancer susceptibility can be detected in the families, i.e. early age of onset, multiple primary tumors, association with other tumor types, and positive family history. syndrome (BHD) (chromophobe RCC/oncocytoma) (10, 11) , and hyperparathyroidism-jaw tumor syndrome (HPT-JT) (cysts, hamartomas, papillary RCC) (45) . In addition, a pediatric tumor of the kidney, Wilms tumor, is estimated to be hereditary in 5%of cases due to mutations in the WT1 and other currently unidentified genes (12) .
The aim of this review is to provide a short description of the currently known inherited cancer syndromes predisposing to renal cell cancer, to help identification of patients in clinical practice. The clinical, histopathological, and genetic features of the best-known forms of inherited RCC of adults will be presented. Diagnosis, genetic counseling, follow-up, and treatment options will also be discussed.
VON HIPPEL-LINDAU DISEASE (VHL)
Von Hippel-Lindau disease is the most common inherited RCC syndrome. It is an autosomal dominant disease caused by germline mutations (see Glossary p. 109) in the VHL gene ( Fig. 1A) . The estimated incidence is 3/100 000 live births (13) and the penetrance is over 90 % by the age of 65 (14) . The disease is characterized by predisposition to angiomas of the retina and hemangioblastomas in central nervous system (CNS), clear cell RCC of the kidney (Table 1 , Fig. 2 ), and pheochromocytomas. In addition, VHL patients may develop other benign and malignant tumors in various organs and cysts particularly in the pancreas and the kidneys (Fig. 2) .
The most common and earliest features of VHL are retinal angiomas and CNS hemangioblastomas, occurring in approximately 60 % of VHL patients. They are diagnosed on average at ages 25 and 30 years, respectively (15) . Hemangioblastomas are usually subtentorial located in the cerebellar hemispheres, spinal cord, and brain stem. Due to their space-occupying nature, they can cause severe morbidity (15) .
Renal lesions, RCC and renal cysts, are present in 60 % of VHL patients (14) . Renal cysts are usually asymptomatic and seldom need treatment, although complex cysts require monitoring (16) . RCC occurs in approximately 25-45 % of the patients and arises usually between the ages of 25 and 58 years (15, 17) . Tumors are typically bilateral and multiple, as many as several hundreds of lesions can be microscopically detected (18) . Carcinomas typically display clear cell histology with solid or a mixture of solid and cystic appearance. Due to the asymptomatic nature of early RCC, screening presymptomatic disease is important in these patients and potentially improves prognosis. Before systematic follow-up became routine, median survival in VHL patients was less than 50 years of age often due to complications related to RCC (15) .
Other tumors in VHL include pheochromocytomas, which are catecholamine-producing tumors arising most often in the adrenal medulla. These are diagnosed in about 15 % of patients, and they tend 2 . A T1-weighted sequence magnetic resonance image (MRI) of a VHL patient. In the left kidney there is a non-homogenous RCC in upper-medial pole (arrowhead) and a homogenous benign cyst (arrow). The cranial pole of the right kidney has been removed due to a previous RCC and cannot be visualized in this section.
to cluster in a subset of families. In addition, VHL patients may develop islet cell tumors of the pancreas, endolymphatic sac tumors, and cysts and cystadenoma in the kidney, pancreas, epididymis and broad ligament.
Based on the occurrence of RCC and pheochromocytoma, VHL has been classified as VHL1 without pheochromocytoma, VHL2A with pheochromocytoma and with low risk of renal cancer, VHL2B with pheochromocytoma and high risk of renal cancer, and VHL2C with pheochromocytoma only (without any other benign or malignant tumors). Recognition of these phenotypes has provided useful information in screening and counseling of affected individuals.
The predisposing gene for VHL is the VHL tumor suppressor gene in the short arm of chromosome 3 (3p25-p26) (5). Characteristic germline mutations have been shown to cause different VHL phenotypes (genotype-phenotype correlation). The gene encodes for the VHL protein, which is implicated in regulation of cellular responses to hypoxia (19, 20) , in control of the cell cycle exit (21) , fibronectin assembly, and extracellular matrix formation (22) . Inactivation of the VHL gene is a critical event not only in the development of tumors from VHL patients but also in the development of sporadic clear cell RCC. Inactivation of both VHL alleles has been observed in over 50 % of sporadic RCCs, specifically clear cell RCCs.
HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a recently identified autosomal dominant tumor syndrome caused by germline mutations in the fumarate hydratase (FH) gene (1q42.1) ( Fig. 1B ) (23) . It is characterized by predisposition to benign leiomyomas of the skin and the uterus (fibroids, myomas). In a subset of families, predisposition to early-onset RCC and uterine leiomyosarcoma can be detected (Table 1) (6, 24) . RCC is typically of papillary type 2 histology.
The most common feature in HLRCC are leiomyomas of the skin and/or the uterus being present in approximately 85 % of patients (25, 26) . The onset of cutaneous leiomyomas has been reported to range from 10 to 47 years and of uterine lesions from 18 to 52 years (25) . Cutaneous leiomyomas present as multiple firm, skin-colored nodules ranging in size from 0.5 to 2 cm ( Fig. 3 ). Uterine leiomyomas in HLRCC are often numerous and large and cause typical symptoms, such as abnormal uterine bleeding and pain. In a subset of families, predisposition to malignant leiomyosarcoma of the uterus has also been observed (6, 27, 28) . Uterine leiomyosarcoma is a rare mesenchymal cancer of the uterine corpus typically associated with a poor prognosis (5-years-survival <50%).
Renal cancer is present in a subset of HLRCC families. So far, 26 patients with renal cancer have been identified in 11 families (6, 24, 25, 29, unpublished data). The mean age at onset is much earlier than in sporadic RCC (median 36 years in Finnish patients). In contrast to other forms of inherited RCC, renal cancers in HLRCC are typically solitary and unilateral (6). Tumors appear to be associated with aggressive disease, as most patients have died of metastatic disease within five years after diagnosis. The specific histology of renal cancers in HLRCC originally led to identification of the syndrome (6). The HLRCC tumors typically display papillary structures with type 2 epithelium and large cells with abundant eosinophilic cytoplasm, large nuclei, and prominent inclusion-like eosinophilic nucleoli (6) (Fig. 4) . The Fuhrman nuclear grade is typically high, from 3 to 4. Interestingly, three HLRCC patients were recently identified with either collecting duct carcinoma or oncocytic tumor (25, 29) .
Germline mutations in FH have been found in 85 % HLRCC families (6, 24, 25, [27] [28] [29] [30] [31] . FH is an enzyme of the mitochondrial tricarboxylic (Krebs) cycle being involved in cellular energy metabolism. Inactivation of both FH alleles has been detected in the great majority of HLRCC tumors, suggesting that FH is a tumor suppressor gene. The mechanism by which the mutations lead to tumor development, however, is presently not understood.
The predisposition to malignancies, RCC or uterine leiomyosarcoma, is found in only 10 % of HLRCC families. Thus, it is suggested that modifying genes or environmental factors could play a role in the development of renal cancer in HLRCC (23, 25, 32) . In sporadic tumors, somatic FH mutations seem to be relatively rare (27, 28, 33) .
HEREDITARY PAPILLARY RENAL CARCINOMA (HPRC)
Hereditary papillary renal cell carcinoma (HPRC) is a rare dominantly inherited form of RCC characterized by predisposition to multiple bilateral papillary renal cell tumors (Table 1) (7, 34). Association of nonrenal malignancies with predisposition to renal cell carcinoma in these families has remained obscure (34) . When compared to HLRCC tumors, the renal carcinomas exhibit type 1 papillary histology with small cells, low-grade basophilic nuclei (mainly Fuhrman grades 1-2), and inconspicuous amphophilic cytoplasm and nucleoli (35) . The disease gene, namely MET proto-oncogene is located on chromosome 7q31 (36) . MET encodes a tyrosine-kinase receptor whose ligand is the hepatocyte growth/scatter factor (HGF) (37) . The gene belongs to the large tyrosine-kinase family of oncogenes. Interestingly, specific inhibitor for one of the members of this protein family, imatinib, has been successfully used in treatment of both chronic myeloid leukemia and gastro-intestinal stromal tumors (GIST) (reviewed in 38).
OTHER INHERITED RCC SYNDROMES
Tuberous sclerosis is a dominantly inherited disease characterized by multiple hamartomas in different organs. CNS lesions cause the clinical manifestations, including learning disability, epilepsy and behavioral problems. The most common renal manifestation are angiomyolipomas, which despite their benign nature, can cause severe morbidity due to hemorrhage or compression of healthy renal tissue (8). On rare occasions, malignant renal tumors can be detected (Table 1) . These are most often clear cell carcinomas, although other histological types have also been observed (39, 40) . Tuberous sclerosis is genetically heterogeneous with two main predisposing genes, TSC1 at 9q34 and TSC2 at 16p13 (41, 42) .
In hereditary non-polyposis colorectal cancer (HNPCC), which is caused by germline mutations in the mismatch repair genes, the most common manifestations are colorectal and endometrial cancers. Affected individuals also have an increased risk of uroepithelial carcinoma of the renal pelvis and ureters (Table 1) , and other malignancies, such as cancers of the stomach, small intestine, ovaries, and hepatobiliary tract (9).
Birt-Hogg-Dube syndrome (BHD) is characterized by three types of cutaneous lesions, i.e. fibrofolliculomas, trichodiscomas, and acrochordons (43) . Renal lesions include variable histological subtypes such as oncocytomas, chromophobe and papillary RCCs, and clear cell carcinomas (Table 1) (10) . The gene for the syndrome, BHD, at 17p11 was recently identified (11) . Interestingly, individuals with BHD also have a high risk for recurrent pneumothorax.
Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a rare autosomal dominant disorder typified by primary hyperparathyroidism caused by parathyroid adenomas. The disease is associated with ossifying fibroma of the jaw and different types of renal lesions including benign cysts, hamartomas, Wilms tumor, and bilateral papillary RCC (Table 1 ) (44) . The gene predisposing to HPT-JT was recently identified as hyperparathyroidism-2 (HRPT2) in 1q21-q31 (45) .
Clear cell RCC has also been reported to segregate in families with a constitutional translocation involving the short arm of chromosome 3 (46, 47) . In addition, clear cell RCC has been reported to cluster in small families with 2 to 4 affected members (familial clear cell renal carcinoma, FCCRC) (48, 49) .
DIAGNOSIS AND GENETIC COUNSELLING
Recent studies have shown that although inherited high-risk predisposition to RCC is rare, occurring in about 2% of cases (3, 4), it is likely that presently unknown low-risk susceptibility genes may actually underlie a much larger proportion of RCC (50) . This is also suggested by the finding that first degree relatives (parents and sibs) of patients have a higher risk of RCC compared to general population (50) (51) (52) . As familial occurrence of RCC is rare, it should always raise suspicion of inherited susceptibility.
The general features of inherited cancer susceptibility include positive family history, young age at diagnosis, bilateral disease or multiple primary tumors, and specific features of known inherited can- 
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cer syndromes present in the patient or family members. When collecting family history, detailed information is needed not only from the index patient but also from other family members. Previous cancer cases in the family should be reviewed and verified from hospital records, which also enables collection of detailed medical information. Data, such as ages at diagnosis and tumor histology, are of paramount importance in assessing the possibility of inherited cancer syndrome, but difficult to obtain through spoken information from the patients only. As this may be complicated and time consuming, a consultation of a clinical geneticist is usually in place. When should a patient with RCC be referred for a genetic consultation? When a patient with RCC has a positive family history, that is first or second-degree relatives with RCC, one should always consider this. Other situations even without a positive family history, which suggest further investigations of a possible inherited cancer predisposition, include patients with RCC diagnosed at an early age (at least those <40 yrs) as the median age of sporadic RCC is around 60 years of age (53) . Namely, less than 5% of kidney cancer patients are diagnosed under the age of 40 (54) . Multiple and bilateral renal tumors or multiple primary tumors of other organs are also an important sign of an inherited risk for cancer. For recognition of some cancer predisposition syndromes, such as VHL, published diagnostic criteria can be used (55) . To help identification of the syndromes including several tumor types, it may be helpful for a clinician to try to recognize the most common tumor or symptom pairs suggesting inherited susceptibility to RCC (Table 1) .
If an inherited cancer syndrome is suspected, the diagnosis can often be confirmed by genetic testing. This, after collection of family data, begins with genetic counseling and, almost invariably, testing of an affected person to identify the specific mutation in the family. If a mutation is found, this allows testing for other, also unaffected family members. Testing unaffected individuals is called predictive testing, as by testing these individuals it is possible to identify people who are at high, but not absolute risk of developing certain tumors or cancers. Testing, however, has many psychological and social implications as well as recommendation of life-long surveillance once a person has been found to be a carrier, and therefore appropriate genetic counseling must be provided prior to testing. On the other hand, by testing it is possible to identify others who have not inherited the disease-predisposing mutation and thus need no regular surveillance. Testing a person for a mutation always has implications for other family members as well. Identification of a dominantly inherited mutation (which mostly is the case with the inherited cancer predisposition) reflects as a 50 % risk for first-degree relatives and may also involve other more distant family members. These at-risk individuals also have to be provided with genetic counseling and testing. True voluntary and information-based decision of genetic testing can only be done, if the people in question are first provided with appropriate information. Finally, iden-tified carriers need to be referred for further consultations for follow-up.
FOLLOW-UP AND TREATMENT
While several suggestions for screening of patients with VHL have been published (13, 14, 56, 57) , there are no established guidelines for screening in patients with rare hereditary RCC. In VHL multidisciplinary follow-up is indicated and screening for RCC is one part of this. Annual abdominal ultrasound is often suggested to begin at the age of 10 years, but this is more due to other abdominal tumors, particularly pheochromocytoma, than RCC. For the other syndromes, the age at which annual radiological controls should be started should be determined by the age distribution of renal cancers. The youngest patients reported with hereditary forms of RCC, however, have been in their teens. Since frequent lifetime radiological examination of patients is necessary, the risks caused by radiation with repeated computed tomography (CT) must also be considered.
In terms of sensitivity, neither CT nor ultrasound is superior for screening for VHL associated renal tumors, and the choice of imaging method is made on the basis of availability and local experience. It is suggested that one should use the same radiological method at each follow-up in order to enhance the identification of any new findings through comparison of consecutive investigations. However, if a suspect lesion is found with ultrasound, intravenous contrast medium enhanced CT or MRI is usually needed for more accurate evaluation (58) .
In papillary forms of RCC (HLRCC and HPRC) renal ultrasound may not be sufficient, since papillary renal tumors are often isoechogenic and thus missed by ultrasound (25) . To avoid the radiation load caused by consecutive CT, MRI would probably be the method of choice, although perhaps not available for annual screening of all patients. Therefore, at this point in time, for HLRCC patients over 18 years of age we suggest screening with renal ultrasound once or twice a year with abdominal CT every other year. Screening of younger patients can be considered individually. When long-time follow-up data on HLRCC patients will become available, the suggested screening procedures must be reviewed. Moreover, as malignancies are present only in a subset of families, it may turn out that the surveillance should be carried out only in some families. Since HPRC is extremely rare, only little information about the progression of this disease is available. Therefore we suggest similar follow-up for both HLRCC and HPRC.
In addition to annual follow-up by urologist, female HLRCC patients need annual screening by gynecologist as well. Although leiomyomas are benign, it is important to note that these patients may develop uterine leiomyomas at an early age, which may affect their fertility. Annual examination with transvaginal ultrasound is safe and readily available to detect uterine leimyomas. Because of the elevated risk for uterine leiomyosarcoma, hysterectomy is re-commended around the age of 40 for HLRCC patients or when the patients have completed their family.
All radiological methods can miss small renal lesions with a diameter less than 1 cm. It seems that CT is not better than ultrasound in the characterization of small tumors <3 cm in diameter (59) . Therefore, in case unexpected symptoms such as hematuria or unclear abdominal pain occur between the annual controls, the kidneys should readily be examined with urgent ultrasound or CT.
When planning the treatment it is important to identify which specific form of hereditary RCC the patient has, since the operative guidelines vary. In HLRCC the renal tumors tend to be aggressive and metastasize at an early phase. Consequently, radical nephrectomy must be performed shortly after detection of renal tumor in HLRCC patients. In conditions such as VHL, HPRC and BHD, where multiple bilateral tumors are common but usually not very aggressive by nature, nephron sparing surgery is the primary choice. The objective of this is to preserve renal function and to avoid dialysis and transplantation as long as possible, while reducing the risk of metastases. It has been shown in several studies that at least in VHL and HPRC, using tumor size of 3 cm as the threshold for nephron sparing surgery will allow effective therapeutic procedure to minimize the risk for metastatic disease while maximizing the remaining renal function (60) (61) (62) (63) .
DISCUSSION
As in many other types of cancer, most cases of RCC are not due to inherited predisposition. While only a small proportion of RCC is caused by hereditary susceptibility, it is important to recognize the families with these, mostly rare conditions. The correct diagnosis will enable genetic testing and identification of at risk individuals while excluding the high cancer risk in other family members. By regular follow-up and correct choice of treatment, it is possible to improve the prognosis and quality of life of these patients. The urologists who treat patients with RCC are in the position to identify patients at risk and should readily use genetic consultations in cases suggestive of inherited cancer predisposition.
